Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

Hannover Medical School, Department of Gastroenterology, Hepatology, and Endocrinology, Center for Internal Medicine, Hannover, Germany.
Journal of Hepatology (Impact Factor: 9.86). 11/2010; 54(6):1114-22. DOI: 10.1016/j.jhep.2010.08.040
Source: PubMed

ABSTRACT BI201335 is a highly specific and potent HCV protease inhibitor. This multiple rising dose trial evaluated antiviral activity and safety in chronic HCV genotype-1 patients.
Thirty-four treatment-naïve patients were randomized to monotherapy with placebo or BI201335 at 20-240 mg once-daily for 14 days, followed by combination with pegylated interferon alfa/ribavirin (PegIFN/RBV) through Day 28. Nineteen treatment-experienced patients received 48-240 mg BI201335 once-daily with PegIFN/RBV for 28 days. HCV-RNA was measured with Roche COBAS TaqMan.
In treatment-naïve patients, median maximal viral load (VL) reductions during 14-day monotherapy were -3.0, -3.6, -3.7, and -4.2 log(10) for the 20, 48, 120, and 240 mg groups. VL breakthroughs (≥1 log(10) from nadir) were seen in most patients on monotherapy and were caused by NS3/4A variants (R155K, D168V) conferring in vitro resistance to BI201335. Adding PegIFN/RBV at Days 15-28 led to continuous viral load reductions in most patients. In treatment-experienced patients, treatment with BI201335 and PegIFN/RBV achieved VL<25 IU/ml at Day 28 in 3/6, 4/7, and 5/6 patients in the 48, 120, and 240 mg dose groups. VL breakthroughs were observed during triple combination in only 3/19 patients. BI201335 was generally well tolerated. Mild rash or photosensitivity was detected in four patients. Mild unconjugated hyperbilirubinemia was the only dose-dependent laboratory abnormality of BI201335. BI201335 elimination half-life supports once-daily dosing.
BI201335 combined with PegIFN/RBV was well tolerated and induced strong antiviral responses. These results support further development of BI201335 in HCV genotype-1 patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives To examine the safety and efficacy of ombitasvir and ABT-450 with ritonavir(ABT-450/r) +ribavirin(RBV) in treatment-naïve, non-cirrhotic adults with chronic HCV genotype 1-3 infection. Methods Patients in this open-label, exploratory, phase 2, multicenter study received ombitasvir(25mg QD) and ABT-450/r(200/100mg QD) +RBV for 12 weeks. Primary efficacy endpoint was HCV RNA<lower limit of quantitation(LLOQ) from week 4 through 12. Sustained virologic response 12 weeks post-treatment(SVR12) was a secondary endpoint. Results Sixty-one patients were enrolled. Among genotype 1-, 2-, and 3-infected patients, respectively, HCV RNA was<LLOQ from week 4 through 12 in 10(100%; 95% CI 69-100), 9(90%; 56-100), and 7(70%; 35-93) receiving the RBV-containing regimen and 9(90%; 56-100), 8(80%; 44-97), and 2(18%; 2-52) receiving the RBV-free regimen. Among genotype 1-, 2-, and 3-infected patients, respectively, SVR12 was achieved by 10(100%), 8(80%), and 5(50%) receiving the RBV-containing regimen, and 6(60%), 6(60%), and 1(9%) receiving the RBV-free regimen. The most common adverse events were fatigue, nausea, and headache. One patient discontinued due to an adverse event. Conclusions In this study, ombitasvir and ABT-450/r +RBV regimens were generally well-tolerated. Sustained virologic response was achieved in most patients with HCV genotype 1 or 2 infection, but low SVR rates were observed in HCV genotype 3-infected patients.
    Journal of Infection 09/2014; 70(2). DOI:10.1016/j.jinf.2014.09.008 · 4.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Asunaprevir (ASV), an isoquinoline based competitive inhibitor targeting the Hepatitis C Virus (HCV) NS3/4A protease, is very potent in vivo. However the potency is significantly compromised by the drug resistance mutations R155K and D168A. In this study three crystal structures of ASV and an analog were determined to analyze the structural basis of drug resistance susceptibility. These structures revealed that ASV makes extensive contacts with Arg155 outside the substrate envelope. Arg155 in turn is stabilized by Asp168, thus when either residue is mutated the enzyme's interaction with ASV's P2* isoquinoline is disrupted. Adding a P1-P3 macrocycle to ASV enhances the inhibitor's resistance barrier likely due to poising the inhibitor to its bound conformation. Macrocyclic inhibitors with P2* extension moieties avoiding interaction with the protease S2 residues including Arg155 must be chosen for future design of more robust protease inhibitors.
    ACS Chemical Biology 09/2014; DOI:10.1021/cb5006118 · 5.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The flaviviruses dengue, West Nile, and Japanese encephalitis represent three major mosquito-borne viruses worldwide. These pathogens impact the lives of millions of individuals and potentially could affect non-endemic areas already colonized by mosquito vectors. Unintentional transport of infected vectors (Aedes and Culex spp.), traveling within endemic areas, rapid adaptation of the insects into new geographic locations, climate change, and lack of medical surveillance have greatly contributed to the increase in flaviviral infections worldwide. The mechanisms by which flaviviruses alter the immune and the central nervous system have only recently been examined despite the alarming number of infections, related deaths, and increasing global distribution. In this review, we will discuss the expansion of the geographic areas affected by flaviviruses, the potential threats to previously unaffected countries, the mechanisms of pathogenesis, and the potential therapeutic interventions to limit the devastating consequences of these viruses.
    Journal of NeuroVirology 10/2014; DOI:10.1007/s13365-014-0285-z · 3.32 Impact Factor

Full-text (2 Sources)

Available from
May 22, 2014